TITLE

Cutting the risk of complications

PUB. DATE
October 1994
SOURCE
USA Today Magazine;Oct94, Vol. 123 Issue 2593, p15
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports on two studies on diabetes and resulting serious complications. Intensive treatment of insulin-dependent diabetics reducing complications; Ability of angiotensin captopril to slow the advance of kidney damage.
ACCESSION #
9410194117

 

Related Articles

  • Diabetes and intensive blood glucose control.  // American Family Physician;11/15/1993, Vol. 48 Issue 7, p1306 

    Presents a study of Wang and colleagues reported in `Lancet', May 22, 1993 issue on the effect of intensive therapy on the development of diabetic retinopathy and nephropathy. Effect of long-term intensive blood glucose control; Effect of continuous subcutaneous insulin infusion.

  • Mixing medicine & diabetes. Abramovitz, Melissa // Countdown;Summer95, Vol. 16 Issue 3, p16 

    Provides advice on the use of medicines in the treatment of other diseases related to diabetics. Evaluation of each drug in the context of treating the disease; Hard and fast rules that apply to diabetics on medication; Avoiding sympathomimetic and diuretic drugs; Nature of steroids; Risks...

  • Treatment of Dyslipidaemia with Fluvastatin in Patients with Type 2 Diabetes Mellitus: Effects on Lipids, Mental State and Fibrinolysis. Visseren, F.L.J.; Bouter, P.K.; van Loon, B.J.P.; Erkelens, W.D. // Clinical Drug Investigation;2001, Vol. 21 Issue 10, p671 

    Objective: To determine the effects of fluvastatin on lipids, mood and fibrinolysis in dyslipidaemic patients with type 2 diabetes mellitus. Design and Setting: Randomised, double-blind, placebo-controlled study in 12 outpatient clinics of general hospitals in The Netherlands evaluating the use...

  • Commentary: Economics of diabetes care must move forwards. Home, P.D. // BMJ: British Medical Journal (International Edition);12/16/95, Vol. 311 Issue 7020, p1599 

    Opinion. Focuses on the economics of diabetes care and its needs. Management of diabetes mellitus as for the most part preventive medicine; Reason for difficulty in judgments between the present and in the future in both health and economic terms; Issues related to the degree of benefit of...

  • Acute complications. Peragallo-Dittko, Virginia; Robertson, Carolyn; Hurley, Mary Lou; Begany, Timothy // RN;Aug95, Vol. 58 Issue 8, p36 

    Discusses the treatment of the acute complications of diabetes. Signs of hypoglycemia; Risk factors for hypoglycemia; Treatment of diabetic ketoacidosis; Detection of hyperglycemic hyperosmolar nonketotic syndrome.

  • Zenarestat: FK 366, FR 74366, FR 901366.  // Drugs in R&D;2002, Vol. 3 Issue 4, p235 

    Adis Comments Zenarestat [FK 366, FR 74366, FR 901366] is an orally active quinazoline derivative aldose reductase inhibitor under development with Fujisawa for the treatment of diabetic complications (neuropathy, retinopathy and cataracts). It was licensed to Parke-Davis (formerly a division of...

  • Managing hypertension in patients with diabetes.  // Patient Care;1/30/1994, Vol. 28 Issue 2, p15 

    Discusses the treatment of hypertension in diabetic patients. Urgency in the determination of the appropriate treatment of the hypertensive diabetic; Necessary lifestyle changes; Angiotensin converting enzyme inhibitors as drugs of choice.

  • The effect of intensive diabetes therapy on the development and progression of neuropathy.  // Annals of Internal Medicine;4/15/95, Vol. 122 Issue 8, p561 

    Examines the effect of intensive diabetes therapy on the development and progression of neuropathy. Effect on the risk of attaining neurologic outcomes at five years; Effect on somatic and autonomic nerve functions; Pathogenetic mechanisms responsible for the progressive loss and damage of...

  • Diabetic macular edema may be amenable to drugs. Charters, Lynda; Aiello, L. Paul // Ophthalmology Times;03/01/2001, Vol. 26 Issue 5, p49 

    Reports that pharmacologic therapy may serve as a potential treatment for diabetic macular edema. Pathology; Primary defect in diabetes; Structure for the maintenance of vessel barrier function.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics